Brian D. Brown, Ph.D., Technology Impact Award RecipientIcahn School of Medicine at Mount Sinai

The CRI award is letting us establish really novel technologies that will enable us to discover the next generation of cancer immunotherapy targets
Area of Research: All Cancers

Cancer immunotherapy is revolutionizing the treatment of many cancers. In particular, checkpoint inhibitors that block the immune system’s “brakes”—such as PD-1 and CTLA-4—are allowing many patients to experience long-term benefits and, in some cases, cure-like responses. Though there has been a great deal of success, not all patients respond to these current checkpoint immunotherapies because alternative brakes can shut down T cells, and tumors can evolve additional mechanisms to prevent immune-mediated elimination.

Therefore, to develop new immunotherapy drugs, Dr. Brown seeks to identify additional pathways that control the immune system's response to cancer. To do this, his team is employing a novel technology that enables rapid analysis of hundreds of genes at once in order to identify genes that control the immune system's others brakes and accelerators, which will help determine how cancers evade immune responses. As a first application of the platform, he is using it to find genes that are critical for enabling T cells to eliminate breast tumors. These studies, and the technology he’s developing, will greatly aid the development of new drugs to turn on the immune system and help it to eliminate cancers.

Projects and Grants

Development of a novel technology for cancer immunology target discovery

Icahn School of Medicine at Mount Sinai | All Cancers | 2019

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.